[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552339":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":48,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":10,"maxAge":10,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Henan Province Clinical Research Center for Cardiovascular Diseases","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"acute myocardial infarction (AMI)",null,"acute myocardial infarction",{"label":13,"type":10,"description":14,"interventionNames":10},"Unstable angina (UA)","Unstable angina",{"label":16,"type":10,"description":17,"interventionNames":10},"chronic coronary syndrome (CCS)","chronic coronary syndrome",{"label":19,"type":10,"description":20,"interventionNames":10},"normal coronary artery (NCA)","normal coronary artery",[22],{"name":23,"affiliation":24,"role":25},"Junnan Tang, Director","Department of Cardiology, The First Affiliated Hospital of Zhengzhou University","STUDY_CHAIR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Junnan Tang, Chair","CONTACT","+86 37166295219","fcctangjn@zzu.edu.cn",{"name":33,"role":29,"phone":10,"phoneExt":10,"email":34},"Jinying Zhang, Director","jyzhang@zzu.edu.cn",[36],{"facility":24,"status":10,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":10},"Zhengzhou","Henan","450018","China","CN",{"type":43,"coordinates":44},"Point",[45,46],113.64861,34.75778,{"lat":46,"lon":45},{"type":49,"investigatorFullName":50,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ge Zhang","100552339","multi-omics-merge-for-ensemble-subtyping-for-atherosclerotic-cardiovascular-disease-100552339",false,"NCT06471803","Multi-omics Merge for Ensemble Subtyping for Atherosclerotic Cardiovascular Disease","Multi-omics Merge for Ensemble Subtyping for Atherosclerotic Cardiovascular Disease and Related Mechanism Study","ASCVD-MOMENT","Inclusion Criteria:\n\n1. aged more than 18 years\n2. meet the diagnostic criteria of coronary heart disease\n3. undergo coronary angiography after admission and have at least 50% stenosis in at least one major coronary artery\n4. able to sign the informed consent form\n\nExclusion Criteria:\n\n1. severe valvular disease (defined as valvular disease stage C or D)\n2. hypertrophic cardiomyopathy; pulmonary heart disease 2) gastrointestinal disease\n3. hyperthyroidism, anemia, or any other high-intensity heart disease\n4. malignant tumors\n5. severe dysfunction of the liver (defined as alanine aminotransferase or total bilirubin greater than 3 times the upper limit of normal) or kidney (defined as eGFR) \\>20 mL\u002Fmin\u002F1.73m2 or requiring dialysis)\n6. severe congenital heart disease\n7. severe infectious or contagious disease\n8. autoimmune disease\n9. age \\\u003C18 years\n10. patients with incomplete clinical records","ALL",{"count":61,"type":62},500,"ESTIMATED","2 Years","OBSERVATIONAL","The current biological issues driving the evolutionary progression of coronary artery disease are in focus: at this stage, the biological evidence for them is scarce and small in scale, with the exception of metabolomics and microbiomics. Issues such as histologic mapping of coronary atherosclerosis deterioration remain to be corroborated by more clinical and basic evidence! By analyzing the clinical data and multi-omics data of patients with coronary heart disease, investigators will explore the related risk factors and establish molecular subtypes and prognostic prediction models for individualized prediction of coronary heart disease risk, in order to guide the clinical screening of high-risk groups of coronary heart disease and formulate more targeted intervention countermeasures.",[67],"Atherosclerotic Cardiovascular Diseases","NOT_YET_RECRUITING","2024-06-23",{"date":71,"type":72},"2024-06-25","ACTUAL",{"date":74,"type":62},"2024-09-01",{"date":76,"type":62},"2026-03-01",{"name":5,"class":6},1]